Agilent Announces New Class 1 Triple Quadrupole LC/MS System
March 30 2020 - 08:00AM
Business Wire
Purpose-built and validated for clinical laboratories
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent
K6460S Clinical Edition TQ LC/MS system, designed to improve in
vitro diagnostic workflows in clinical labs.
Agilent’s next-generation clinical edition triple quadrupole
LC/MS system, the K6460S, is listed as a Class I medical device
with the U.S. Food and Drug Administration. The system includes a
preconfigured liquid chromatograph and mass spectrometer, as well
as the clinical edition of Agilent MassHunter software, which
provides an easy-to-use and intuitive submission-to-reporting
workflow.
When performing diagnostic assays, the K6460S provides the
specificity and selectivity that clinical labs require, delivering
robust results with more accuracy, and increasing the reliability
of target compound detection in complex matrices.
“We are pleased to announce the launch of the K6460S, our newly
validated LC/MS system in the United States,” said Monty Benefiel,
vice president and general manager of Agilent's Mass Spectrometry
Division. “Agilent has a strong reputation in providing reliable
and routine solutions to clinical laboratories. We believe that the
strength and robustness of our technologies, combined with our
depth of expertise in our services and support offerings, makes
Agilent a powerful partner for clinical diagnostic labs.”
“Using TQ LC/MS increases the specificity, selectivity, and
accuracy of many clinical diagnostic assays compared to traditional
binding assays,” said Ken Lewis, chief executive officer of OpAns,
LLC. “The fully validated Agilent K6460S is a robust and reliable
platform that boosts productivity via technology purpose-built for
diagnostic workflows.”
It was also announced in January 2020 that the Agilent LC-MS/MS
had been approved by China's national drug administration (NMPA)
for use in the China domestic clinical diagnosis market.
Agilent is a leader in providing IVD medical devices to improve
the quality of health care globally and has driven investment in
this key area to develop and launch robust, reliable LC-MS/MS IVD
systems. These instruments improve and simplify the analysis of
samples and address specific workflows to expedite the efficacy of
clinical diagnostics.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200330005195/en/
Media Contact Naomi Goumillout Agilent Technologies
+1.781.266.2819 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024